登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Irinotecan Liposome in Combination With Capecitabine
ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由中国医学科学院肿瘤医院深圳医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06578052,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
history of pulmonary hemorrhage/coughing up ≥ grade 2 (defined as at least 2.5 mL of bright red blood) within 1 month prior to the first dose of drug;
排除标准第 17 条
use of strong inhibitors or inducers of CYP3A4, CYP2C8, and UGT1A1 within 14 days prior to receiving study drug therapy
排除标准第 20 条
Eastern Cooperative Oncology Group (ECOG) physical status score: 0-2;
入选标准第 6 条
absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L, platelets ≥ 100 x 10\^9/L and hemoglobin ≥ 90 g/L (not transfused with blood, blood products, or corrected with granulocyte colony-stimulating factor or other hematopoietic-stimulating factor in the 14 days prior to the laboratory test);
入选标准第 8 条
Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT ≤2.5 times the upper limit of normal value.
入选标准第 9 条
patients with at least one measurable target lesion according to RECIST 1.1 criteria;
入选标准第 5 条
active hepatitis B or C infection (hepatitis B virus surface antigen positive and hepatitis B virus DNA greater than 1x103 copies/mL; hepatitis C virus RNA greater than 1x103 copies/mL), except for asymptomatic chronic hepatitis B or hepatitis C carriers;
排除标准第 10 条
human immunodeficiency virus (HIV) infection (HIV-positive);
排除标准第 11 条
pregnant and lactating women and patients of childbearing age who do not wish to use contraception;
排除标准第 14 条
pregnant or lactating female patients, subjects of childbearing age who refuse to accept contraception; -
排除标准第 22 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06578052,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
patients were fully aware of the study, participated voluntarily and signed the informed consent form (ICF); aged ≥18 years and ≤80 years; patients with histopathologically confirmed unresectable/metastatic pancreatic cancer; imaging-confirmed tumor progression after prior treatment with a standard first-line regimen; patients with at least one measurable target lesion according to RECIST 1.1 criteria; Eastern Cooperative Oncology Group (ECOG) physical status score: 0-2; expected survival time ≥ 3 months; absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L, platelets ≥ 100 x 10\^9/L and hemoglobin ≥ 90 g/L (not transfused with blood, blood products, or corrected with granulocyte colony-stimulating factor or other hematopoietic-stimulating factor in the 14 days prior to the laboratory test); Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT ≤2.5 times the upper limit of normal value.排除标准:Exclusion Criteria:
hypersensitivity to any of the study drugs or their components; concomitant serious uncontrolled concurrent infections or other serious uncontrolled concomitant diseases, moderate or severe renal impairment; (e.g., progressive infections, uncontrollable hypertension, diabetes mellitus, etc.); cardiac function and disease consistent with one of the following conditions Long QTc syndrome or QTc interval >480 ms; Complete left bundle branch block, degree II or degree III atrioventricular block; Severe, uncontrolled arrhythmia requiring pharmacologic therapy; New York Society of Cardiology classification ≥ grade III; Cardiac ejection fraction (LVEF) less than 50%; History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormality within 6 months prior to recruitment. active hepatitis B or C infection (hepatitis B virus surface antigen positive and hepatitis B virus DNA greater than 1x103 copies/mL; hepatitis C virus RNA greater than 1x103 copies/mL), except for asymptomatic chronic hepatitis B or hepatitis C carriers; human immunodeficiency virus (HIV) infection (HIV-positive); imaging confirmation of intestinal obstruction; previous or current concurrent other malignancies (except effectively controlled non-melanoma basal cell carcinoma of the skin, carcinoma in situ of the breast/cervix, and other malignancies that have been effectively controlled without treatment within the past five years); pregnant and lactating women and patients of childbearing age who do not wish to use contraception; patients with other malignant tumors requiring treatment; patients who, in the judgment of the investigator, are not suitable for participation in this study. history of pulmonary hemorrhage/coughing up ≥ grade 2 (defined as at least 2.5 mL of bright red blood) within 1 month prior to the first dose of drug; a predisposition to arterial embolism, severe hemorrhage (other than bleeding due to surgery), and severe bleeding within 6 months prior to first dose; a combination of symptomatic brain metastases, meningeal metastases, spinal cord tumor invasion, and spinal cord compression use of strong inhibitors or inducers of CYP3A4, CYP2C8, and UGT1A1 within 14 days prior to receiving study drug therapy who have used other clinical trial medications within 1 month prior to the first dose; pregnant or lactating female patients, subjects of childbearing age who refuse to accept contraception; -
引自 ClinicalTrials.gov, NCT06578052, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06578052,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。